Seattle Genetics Inc., of Bothell, Wash., and Takeda Pharmaceutical Co. Ltd., of Osaka, Japan, reported phase III data showing that Adcetris (brentuximab vedotin) met its primary endpoint in Hodgkin lymphoma patients, with a statistically significant 75 percent improvement in progression-free survival vs. placebo (p = 0.001).